Literature DB >> 11927002

Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

Yasuo Imai1, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshikazu Sugimoto.   

Abstract

Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. In the present study, we found that estrone and 17beta-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562 / BCRP). These estrogens showed only a marginal effect, or none, in parental K562 cells. Estrone and 17beta-estradiol increased the cellular accumulation of topotecan in K562 / BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927002      PMCID: PMC5926974          DOI: 10.1111/j.1349-7006.2002.tb02162.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  16 in total

1.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.

Authors:  M de Bruin; K Miyake; T Litman; R Robey; S E Bates
Journal:  Cancer Lett       Date:  1999-11-15       Impact factor: 8.679

2.  Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.

Authors:  Kumie Kage; Satomi Tsukahara; Tomomi Sugiyama; Sakiyo Asada; Etsuko Ishikawa; Takashi Tsuruo; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  A multidrug resistance transporter from human MCF-7 breast cancer cells.

Authors:  L A Doyle; W Yang; L V Abruzzo; T Krogmann; Y Gao; A K Rishi; D D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 4.  Genetic analysis of the multidrug transporter.

Authors:  M M Gottesman; C A Hrycyna; P V Schoenlein; U A Germann; I Pastan
Journal:  Annu Rev Genet       Date:  1995       Impact factor: 16.830

5.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

6.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

Authors:  R W Robey; Y Honjo; A van de Laar; K Miyake; J T Regis; T Litman; S E Bates
Journal:  Biochim Biophys Acta       Date:  2001-06-06

Review 7.  Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2.

Authors:  D Keppler; I Leier; G Jedlitschky
Journal:  Biol Chem       Date:  1997-08       Impact factor: 3.915

8.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Authors:  M Maliepaard; M A van Gastelen; L A de Jong; D Pluim; R C van Waardenburg; M C Ruevekamp-Helmers; B G Floot; J H Schellens
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

9.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.

Authors:  C P Yang; S G DePinho; L M Greenberger; R J Arceci; S B Horwitz
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

10.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

View more
  15 in total

1.  Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.

Authors:  Abbie C Johnson; Erica S Hammer; Sophie Sakkaki; Sarah M Tremble; Gregory L Holmes; Marilyn J Cipolla
Journal:  Brain Behav Immun       Date:  2017-07-21       Impact factor: 7.217

Review 2.  Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

Authors:  Kristin M Bircsak; Lauren M Aleksunes
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 3.  Placental ABC Transporters: Biological Impact and Pharmaceutical Significance.

Authors:  Anand A Joshi; Soniya S Vaidya; Marie V St-Pierre; Andrei M Mikheev; Kelly E Desino; Abner N Nyandege; Kenneth L Audus; Jashvant D Unadkat; Phillip M Gerk
Journal:  Pharm Res       Date:  2016-09-19       Impact factor: 4.200

Review 4.  Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up.

Authors:  Sagar Agarwal; Anika M S Hartz; William F Elmquist; Björn Bauer
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 5.  Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges.

Authors:  Svetlana Verenich; Phillip M Gerk
Journal:  Mol Pharm       Date:  2010-10-21       Impact factor: 4.939

6.  Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation.

Authors:  Sophie Petropoulos; William Gibb; Stephen G Matthews
Journal:  Biol Reprod       Date:  2010-12-15       Impact factor: 4.285

Review 7.  Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).

Authors:  Yash A Gandhi; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-24       Impact factor: 4.009

8.  Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Authors:  Ivana Gojo; Ming Tan; Hong-Bin Fang; Mariola Sadowska; Rena Lapidus; Maria R Baer; France Carrier; Jan H Beumer; Bean N Anyang; Rakesh K Srivastava; Igor Espinoza-Delgado; Douglas D Ross
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

9.  Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study.

Authors:  Lili Zhang; Kylee L Spencer; V Saroja Voruganti; Neal W Jorgensen; Myriam Fornage; Lyle G Best; Kristin D Brown-Gentry; Shelley A Cole; Dana C Crawford; Ewa Deelman; Nora Franceschini; Angelo L Gaffo; Kimberly R Glenn; Gerardo Heiss; Nancy S Jenny; Anna Kottgen; Qiong Li; Kiang Liu; Tara C Matise; Kari E North; Jason G Umans; W H Linda Kao
Journal:  Am J Epidemiol       Date:  2013-04-03       Impact factor: 4.897

10.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors:  J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.